AP947A - Quaternary ammonium compounds as tachykinin antagonists. - Google Patents

Quaternary ammonium compounds as tachykinin antagonists. Download PDF

Info

Publication number
AP947A
AP947A APAP/P/1998/001262A AP9801262A AP947A AP 947 A AP947 A AP 947A AP 9801262 A AP9801262 A AP 9801262A AP 947 A AP947 A AP 947A
Authority
AP
ARIPO
Prior art keywords
alkyl
phenyl
alkoxy
fluoro
cycloalkyl
Prior art date
Application number
APAP/P/1998/001262A
Other languages
English (en)
Other versions
AP9801262A0 (en
Inventor
Sandra Marina Monaghan
David Alker
Christopher John Burns
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9801262A0 publication Critical patent/AP9801262A0/xx
Application granted granted Critical
Publication of AP947A publication Critical patent/AP947A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
APAP/P/1998/001262A 1997-06-18 1998-06-11 Quaternary ammonium compounds as tachykinin antagonists. AP947A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712882.1A GB9712882D0 (en) 1997-06-18 1997-06-18 Quaternary ammonium compounds

Publications (2)

Publication Number Publication Date
AP9801262A0 AP9801262A0 (en) 1998-06-30
AP947A true AP947A (en) 2001-03-08

Family

ID=10814535

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1998/001262A AP947A (en) 1997-06-18 1998-06-11 Quaternary ammonium compounds as tachykinin antagonists.

Country Status (43)

Country Link
US (2) US6207678B1 (ja)
EP (1) EP0994876B1 (ja)
JP (1) JP3280993B2 (ja)
KR (1) KR100345389B1 (ja)
CN (1) CN1199971C (ja)
AP (1) AP947A (ja)
AR (1) AR012249A1 (ja)
AT (1) ATE275564T1 (ja)
AU (1) AU726027B2 (ja)
BG (1) BG63341B1 (ja)
BR (1) BR9810619A (ja)
CA (1) CA2291975C (ja)
CO (1) CO4940478A1 (ja)
DE (1) DE69826129T2 (ja)
DZ (1) DZ2524A1 (ja)
EA (1) EA002424B1 (ja)
ES (1) ES2227856T3 (ja)
GB (1) GB9712882D0 (ja)
HN (1) HN1998000087A (ja)
HR (1) HRP980337B1 (ja)
HU (1) HUP0003962A3 (ja)
ID (1) ID23410A (ja)
IL (2) IL155621A0 (ja)
IS (1) IS5269A (ja)
MA (1) MA26509A1 (ja)
MY (1) MY136376A (ja)
NO (1) NO995782L (ja)
NZ (1) NZ501286A (ja)
OA (1) OA11235A (ja)
PA (1) PA8452501A1 (ja)
PE (1) PE80099A1 (ja)
PL (1) PL189557B1 (ja)
PT (1) PT994876E (ja)
SI (1) SI0994876T1 (ja)
SK (1) SK283346B6 (ja)
TN (1) TNSN98089A1 (ja)
TR (1) TR199903135T2 (ja)
TW (1) TW479055B (ja)
UA (1) UA62966C2 (ja)
UY (1) UY25045A1 (ja)
WO (1) WO1998057972A1 (ja)
YU (1) YU64699A (ja)
ZA (1) ZA985239B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ505163A (en) * 1997-12-26 2002-11-26 Yamanouchi Pharma Co Ltd Sustained release medicinal compositions comprising an ionic compound with an opposite charge to the ionic active substance
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
DE60129562T2 (de) * 2000-06-12 2008-04-17 The University Of Rochester Methode zur Behandlung von Hitzewallungen durch Verwendung eines Tachykinin-Rezeptor-Antagonisten
WO2002046156A2 (en) * 2000-12-06 2002-06-13 Sepracor, Inc. 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands
WO2003101459A1 (en) * 2002-05-29 2003-12-11 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
CN1980896A (zh) * 2004-05-07 2007-06-13 詹森药业有限公司 咪唑衍生物的可放大合成
AU2008208920A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or R(-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an NK1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0591040A1 (fr) * 1992-09-30 1994-04-06 Sanofi Amides basiques quaternaires comme tachykinines antagonistes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991201A (en) * 1974-06-27 1976-11-09 Janssen Pharmaceutica N.V. 1-(β-Aryl-β-R-ethyl)imidazoles as antimicrobial agents
US5583134A (en) * 1992-09-30 1996-12-10 Sanofi 1-azoniabicyclo[2.2.2] octanes and pharmaceutical compositions in which they are present

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0591040A1 (fr) * 1992-09-30 1994-04-06 Sanofi Amides basiques quaternaires comme tachykinines antagonistes

Also Published As

Publication number Publication date
AU8215398A (en) 1999-01-04
PT994876E (pt) 2005-01-31
ZA985239B (en) 1999-12-17
HRP980337B1 (en) 2003-02-28
PA8452501A1 (es) 2000-05-24
OA11235A (en) 2003-07-09
YU64699A (sh) 2002-06-19
MY136376A (en) 2008-09-30
NZ501286A (en) 2000-07-28
TNSN98089A1 (fr) 2005-03-15
AR012249A1 (es) 2000-09-27
GB9712882D0 (en) 1997-08-20
BG63341B1 (bg) 2001-10-31
BR9810619A (pt) 2000-09-12
EA002424B1 (ru) 2002-04-25
ATE275564T1 (de) 2004-09-15
TR199903135T2 (xx) 2000-04-21
US6207678B1 (en) 2001-03-27
PE80099A1 (es) 1999-08-25
CA2291975A1 (en) 1998-12-23
TW479055B (en) 2002-03-11
ID23410A (id) 2000-04-20
EA199900986A1 (ru) 2000-06-26
HUP0003962A3 (en) 2001-12-28
KR20010013909A (ko) 2001-02-26
DE69826129D1 (de) 2004-10-14
CO4940478A1 (es) 2000-07-24
US6380396B1 (en) 2002-04-30
AU726027B2 (en) 2000-10-26
DZ2524A1 (fr) 2003-02-01
IS5269A (is) 1999-11-23
AP9801262A0 (en) 1998-06-30
HN1998000087A (es) 1998-10-22
WO1998057972A1 (en) 1998-12-23
SK174499A3 (en) 2001-05-10
UA62966C2 (en) 2004-01-15
EP0994876A1 (en) 2000-04-26
CA2291975C (en) 2004-02-10
DE69826129T2 (de) 2005-09-22
HRP980337A2 (en) 1999-02-28
ES2227856T3 (es) 2005-04-01
NO995782L (no) 2000-02-16
IL155621A0 (en) 2003-11-23
IL133079A0 (en) 2001-03-19
NO995782D0 (no) 1999-11-25
SI0994876T1 (en) 2005-02-28
PL337713A1 (en) 2000-08-28
HUP0003962A2 (hu) 2001-04-28
SK283346B6 (sk) 2003-06-03
KR100345389B1 (ko) 2002-07-24
CN1199971C (zh) 2005-05-04
JP3280993B2 (ja) 2002-05-13
MA26509A1 (fr) 2004-12-20
UY25045A1 (es) 2000-09-29
BG103919A (en) 2001-07-31
IL133079A (en) 2004-06-01
JP2000513030A (ja) 2000-10-03
PL189557B1 (pl) 2005-08-31
EP0994876B1 (en) 2004-09-08
CN1260795A (zh) 2000-07-19

Similar Documents

Publication Publication Date Title
US6159982A (en) 2,4-diaminopyrimidine derivates as dopamine D4 receptor antagonist
CN1165532C (zh) 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
CN1720225B (zh) 具有5-羟色胺受体亲和性的n-芳基磺酰-3-取代吲哚及其制备方法和含有其的药物组合物
DE69719350T2 (de) 2-pyrimidinamin derivaten und verfahrens zu deren herstellung
AP947A (en) Quaternary ammonium compounds as tachykinin antagonists.
US9073911B2 (en) Pyrazole derivatives
KR101518660B1 (ko) 헤테로환 아민 유도체
AP1110A (en) Azetidinylpropylpiperidine derivatives and use as tachykinin antagonist.
JP2009524616A (ja) Ｃｎｓ疾患のための４−イミダゾール誘導体の使用
CN101374516A (zh) 取代的咪唑啉的2-咪唑衍生物的用途
CN1198741A (zh) 具有α2受体亲合活性的咪唑衍生物
CN1067655A (zh) 含氮杂环类化合物的氟代烷氧基苄氨基衍生物
US4369184A (en) 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
NO310232B1 (no) 1-(1,2-disubstituert piperidinyl)-4-substituerte piperazinderivater
CZ362092A3 (en) Piperazinyl cyclohexanol and piperidinyl cyclohexanol derivative, process of its preparation and a pharmaceutical preparation containing thereof
IL124309A (en) Aztidinylalkyl derivatives of the N-heterocyclic compounds, the process for their preparation and medicinal preparations containing them for the antagonists of tachycin
Romanelli et al. Structure− affinity relationships of a unique nicotinic ligand: N-dimethyl-N4-phenylpiperazinium iodide (DMPP)
US5286735A (en) Derivatives of 4-aminomethylpiperidine, their preparation and their use as therapeutics
CA2240964C (en) Piperidone tachykinin antagonists
US5846965A (en) 3-aza and 3-oxa piperidone tachykinin antagonists
Karataş et al. Synthesis and potent in vitro activity of novel 1H‐benzimidazoles as anti‐mrsa agents
JP2004525184A (ja) Ｎｋ−３およびｎｋ−２受容体アンタゴニストとしての３−置換キノリン−４−カルボキサミド誘導体
US9957261B2 (en) 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives
EP0962457B1 (en) Piperidones as tachykinin antagonists
HU177410B (en) Process for preparing new piperidino-propanol derivatives